Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18777688 | METHOD FOR IMPROVING CELL ADHESION WITH SMECTITE CLAY | July 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18777712 | CELL ADHESION METHOD WITH SODIUM MONTMORILLONITE | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18777706 | METHOD OF INCREASING CELL ADHESION WITH PALYGORSKITE | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 17932836 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | September 2022 | June 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17717254 | ANTIBODY POLYPEPTIDES AND USES THEREOF | April 2022 | June 2025 | Allow | 38 | 1 | 1 | No | No |
| 17064505 | COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH | October 2020 | January 2025 | Abandon | 52 | 3 | 1 | Yes | No |
| 16611818 | A Cell Model For In Vitro Evaluation Of Compound-Induced Skin Sensitization And A Constructing Method Therefor | November 2019 | August 2024 | Allow | 57 | 2 | 0 | No | No |
| 15775791 | TRANSDUCTION BUFFER | May 2018 | June 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 15652000 | CELLS GENETICALLY MODIFIED TO COMPRISE PANCREATIC ISLET GLUCOKINASE AND USES THEREOF | July 2017 | May 2020 | Allow | 34 | 2 | 0 | Yes | No |
| 14247145 | CONTROLLABLE ON-OFF METHOD FOR FISH REPRODUCTION | April 2014 | September 2015 | Allow | 17 | 1 | 0 | No | No |
| 13835806 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO VACCINES | March 2013 | April 2015 | Allow | 25 | 3 | 0 | Yes | No |
| 13709005 | LIPOSOMES WITH IMPROVED DRUG RETENTION FOR TREATMENT OF CANCER | December 2012 | December 2013 | Allow | 12 | 2 | 0 | Yes | No |
| 13698804 | CATIONIC LIPIDS | November 2012 | January 2014 | Allow | 14 | 2 | 0 | No | No |
| 13566892 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO VACCINES | August 2012 | December 2014 | Allow | 28 | 4 | 0 | Yes | No |
| 13321093 | POLYNUCLEOTIDE DELIVERING COMPLEX FOR TARGET CELL | November 2011 | February 2014 | Allow | 27 | 1 | 0 | No | No |
| 13296163 | NUCLEIC ACID LIGANDS TO LL37 | November 2011 | May 2014 | Abandon | 30 | 2 | 0 | Yes | No |
| 13124434 | METHOD FOR INTRODUCING GENE INTO CELL, AND COMPOSITION FOR USE IN THE METHOD | April 2011 | November 2012 | Allow | 19 | 2 | 0 | Yes | No |
| 12747123 | ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING NON-LAMELLAR FORMING LIPIDS | September 2010 | December 2013 | Allow | 42 | 3 | 0 | Yes | No |
| 12311554 | ARTIFICIALLY SYNTHESIZED PEPTIDE | January 2010 | March 2012 | Allow | 35 | 1 | 0 | No | No |
| 12513237 | METHOD OF PRODUCING MICROCAPSULES | January 2010 | August 2014 | Allow | 60 | 3 | 0 | No | No |
| 12691566 | POLYMERIC CARRIER FOR DELIVERY OF SMALL INTERFERING RNA | January 2010 | July 2011 | Allow | 18 | 1 | 0 | No | No |
| 12573281 | REMEDY FOR THE TREATMENT OF CARDIO-VASCULAR DISEASES OR DISORDERS | October 2009 | October 2014 | Allow | 60 | 4 | 1 | Yes | No |
| 12249676 | LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER | October 2008 | January 2012 | Allow | 39 | 3 | 0 | No | No |
| 12163317 | EUBACTERIAL TMRNA SEQUENCES AND USES THEREOF | June 2008 | September 2010 | Allow | 27 | 1 | 0 | No | No |
| 12163512 | EUBACTERIAL TMRNA SEQUENCES AND USES THEREOF | June 2008 | August 2010 | Allow | 26 | 1 | 0 | No | No |
| 12163337 | EUBACTERIAL TMRNA SEQUENCES AND USES THEREOF | June 2008 | November 2010 | Allow | 28 | 1 | 0 | No | No |
| 12163564 | EUBACTERIAL TMRNA SEQUENCES AND USES THEREOF | June 2008 | March 2010 | Allow | 21 | 0 | 0 | No | No |
| 12163371 | EUBACTERIAL TMRNA SEQUENCES AND USES THEREOF | June 2008 | September 2010 | Allow | 27 | 1 | 0 | No | No |
| 11886113 | SKIN EQUIVALENT CULTURE | June 2008 | November 2011 | Allow | 50 | 1 | 0 | No | No |
| 11951800 | Medicaments for Chemotherapeutic Treatment of Disease | December 2007 | August 2013 | Allow | 60 | 4 | 0 | Yes | No |
| 11939487 | Bioactive Agent-Loaded Heart-Targeting Nanoparticles | November 2007 | December 2013 | Allow | 60 | 2 | 0 | No | Yes |
| 11666736 | Liposome And Method For Injecting Substance To Cell Using This Liposome | November 2007 | December 2014 | Allow | 60 | 4 | 1 | Yes | Yes |
| 11838589 | METHODS AND COMPOSITIONS FOR ALTERING MUCUS SECRETION | August 2007 | January 2011 | Allow | 41 | 1 | 1 | No | No |
| 11777715 | GENERATION OF ELECTROPOTENTIAL USING BACTERIAL CULTURE | July 2007 | March 2010 | Allow | 32 | 2 | 0 | Yes | No |
| 10573385 | PROCESS FOR PRODUCING CMP-N-ACETYLNEURAMINIC ACID | May 2007 | March 2013 | Allow | 60 | 6 | 0 | Yes | No |
| 11622156 | CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES | January 2007 | December 2012 | Allow | 60 | 3 | 1 | No | Yes |
| 11641551 | IMMUNOSTIMULATORY ACTIVITY OF IMMUNE MODULATORY OLIGONUCLEOTIDES (IMOTM) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS | December 2006 | February 2010 | Allow | 60 | 1 | 1 | No | No |
| 10558216 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | May 2006 | December 2010 | Allow | 60 | 3 | 1 | Yes | No |
| 10560932 | SPHINGOLIPIDS POLYALKYLAMINE CONJUGATES FOR USE IN TRANSFECTION | May 2006 | March 2012 | Allow | 60 | 3 | 1 | No | No |
| 10577447 | ANTITUMOR MEDICINE | April 2006 | October 2009 | Allow | 42 | 4 | 0 | No | No |
| 11396743 | DELIVERY SYSTEM FOR NUCLEIC ACIDS | April 2006 | January 2010 | Allow | 46 | 1 | 1 | Yes | No |
| 11396081 | POLYARGININE-MODIFIED LIPOSOME HAVING NUCLEAR ENTRY ABILITY | March 2006 | August 2013 | Allow | 60 | 8 | 1 | Yes | Yes |
| 11367228 | POLYMERIC CARRIER FOR DELIVERY OF SMALL INTERFERING RNA | March 2006 | January 2010 | Allow | 46 | 4 | 1 | No | No |
| 10570511 | Novel Vector And Utilization Of The Same | February 2006 | December 2012 | Allow | 60 | 7 | 1 | Yes | No |
| 10558538 | METHODS OF DIAGNOSING, PROGNOSING AND TREATING BREAST CANCER | February 2006 | August 2009 | Allow | 44 | 1 | 1 | Yes | No |
| 11329230 | EUBACTERIAL TMRNA SEQUENCES AND USES THEREOF | January 2006 | June 2009 | Allow | 41 | 2 | 1 | Yes | No |
| 10938184 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | September 2004 | October 2008 | Allow | 49 | 2 | 0 | Yes | No |
| 10901471 | PENTOSE-FERMENTATIVE TRANSFORMED ZYMOBACTER MICROORGANISMS | July 2004 | February 2009 | Allow | 60 | 2 | 1 | Yes | No |
| 10883009 | DSRNA INDUCED SPECIFIC AND NON-SPECIFIC IMMUNITY IN CRUSTACEANS AND OTHER INVERTEBRATES AND BIODELIVERY VEHICLES FOR USE THEREIN | July 2004 | September 2013 | Allow | 60 | 8 | 1 | Yes | Yes |
| 10478771 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEIC MOLECULES | November 2003 | August 2010 | Allow | 60 | 4 | 1 | No | No |
| 10641962 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | August 2003 | February 2007 | Allow | 42 | 1 | 1 | Yes | No |
| 10297788 | POSITIVELY-CHARGED PEPTIDE NUCLEIC ACID ANALOGS WITH IMPROVED PROPERTIES | June 2003 | November 2009 | Allow | 60 | 6 | 0 | Yes | No |
| 10442435 | CHOLESTEROL AND HEDGEHOG SIGNALING | May 2003 | September 2011 | Allow | 60 | 8 | 1 | No | Yes |
| 10302814 | METHOD OF TREATING HEPATITIS DELTA VIRUS INFECTION | November 2002 | November 2008 | Allow | 60 | 4 | 1 | No | Yes |
| 10194213 | PHARMACEUTICAL COMPOSITION FOR BORON NEUTRON CAPTURE THERAPY CONTAINING TRIPHENYLBOROXIN | July 2002 | September 2005 | Allow | 38 | 1 | 0 | Yes | No |
| 10189360 | COMPOSITIONS CONTAINING NUCLEIC ACIDS AND LIGANDS FOR THERAPEUTIC TREATMENT | July 2002 | June 2006 | Allow | 47 | 2 | 0 | Yes | No |
| 10158761 | DELIVERY SYSTEM FOR NUCLEIC ACIDS | May 2002 | October 2005 | Allow | 41 | 2 | 1 | Yes | No |
| 10089312 | LIPOSOME-ENTRAPPED DNA ORAL VACCINES | March 2002 | September 2005 | Allow | 42 | 2 | 1 | No | No |
| 10102094 | NUCLEOZYMES | March 2002 | February 2006 | Allow | 47 | 0 | 0 | Yes | No |
| 10031021 | NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA-FETOPROTEIN | March 2002 | October 2005 | Allow | 45 | 3 | 1 | Yes | No |
| 10082973 | TISSUE-SPECIFIC AND TARGET RNA-SPECIFIC RIBOZYMES | February 2002 | December 2009 | Allow | 60 | 9 | 0 | Yes | Yes |
| 09958206 | EUBACTERIAL TMRNA SEQUENCES AND USES THEREOF | February 2002 | September 2005 | Allow | 47 | 2 | 2 | No | No |
| 10060009 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND REPAIR OF DEFECTS OR LESIONS IN ARTICULAR CARTILAGE USING SYNOVIAL-DERIVED TISSUE OR CELLS | January 2002 | February 2008 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 09914020 | METHOD AND COMPOSITIONS FOR ALTERING MUCUS SECRETION | December 2001 | April 2007 | Allow | 60 | 5 | 1 | Yes | No |
| 10007805 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER | December 2001 | January 2008 | Allow | 60 | 7 | 1 | Yes | Yes |
| 10022127 | HUMAN SUPPRESSOR TRNA OLIGONUCLEOTIDES AND METHODS OF USE FOR SAME | October 2001 | October 2005 | Allow | 48 | 4 | 0 | Yes | No |
| 09920033 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | August 2001 | May 2010 | Allow | 60 | 11 | 1 | Yes | Yes |
| 09900355 | MEDICAMENTS FOR CHEMOTHERAPEUTIC TREATMENT OF DISEASE | July 2001 | August 2009 | Allow | 60 | 11 | 1 | No | No |
| 09753169 | OLIGONUCLEOTIDE INHIBITORS OF BCL-XL | January 2001 | February 2006 | Allow | 60 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner EPPS-SMITH, JANET L.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner EPPS-SMITH, JANET L works in Art Unit 1646 and has examined 66 patent applications in our dataset. With an allowance rate of 93.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner EPPS-SMITH, JANET L's allowance rate of 93.9% places them in the 82% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by EPPS-SMITH, JANET L receive 3.21 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by EPPS-SMITH, JANET L is 47 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -4.7% benefit to allowance rate for applications examined by EPPS-SMITH, JANET L. This interview benefit is in the 3% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 91.7% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 90.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.4% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 36.4% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.9% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.